Related Experiment Video
Updated: Jun 15, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges
Zuber Khan1, Ghanshyam Das Gupta2, Sidharth Mehan1
1Division of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, IK Gujral Punjab Technical University, Jalandhar 144603, India.
Abstract:
Multiple sclerosis (MS) is a chronic autoimmune disease that impacts the central nervous system and can result in disability. Although the prevalence of MS has increased in India, diagnosis and treatment continue to be difficult due to several factors. The present study examines the difficulties in detecting and treating multiple sclerosis in India. A lack of MS knowledge among healthcare professionals and the general public, which delays diagnosis and treatment, is one of the significant issues. Inadequate numbers of neurologists and professionals with knowledge of MS management also exacerbate the situation. In addition, MS medications are expensive and not covered by insurance, making them inaccessible to most patients. Due to the absence of established treatment protocols and standards for MS care, India's treatment techniques vary. In addition, India's population diversity poses unique challenges regarding genetic variations, cellular and molecular abnormalities, and the potential for differing treatment responses. MS is more difficult to accurately diagnose and monitor due to a lack of specialized medical supplies and diagnostic instruments. Improved awareness and education among healthcare professionals and the general public, as well as the development of standardized treatment regimens and increased investment in MS research and infrastructure, are required to address these issues. By addressing these issues, it is anticipated that MS diagnosis and treatment in India will improve, leading to better outcomes for those affected by this chronic condition.
Insights
Diagnosing and treating multiple sclerosis (MS) in India is challenging due to limited awareness, insufficient specialists, and high medication costs. Addressing these issues is crucial for improving care for MS patients in India.
Area of Science:
- Neurology
- Immunology
- Public Health
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, with increasing prevalence in India.
- Diagnosis and treatment of MS in India face significant hurdles, impacting patient outcomes.
Purpose of the Study:
- To examine the specific difficulties encountered in the detection and treatment of multiple sclerosis within the Indian context.
- To identify key factors hindering effective MS management in India.
Main Methods:
- The study involved an examination of existing challenges in MS diagnosis and treatment in India.
- Analysis focused on factors such as healthcare professional and public awareness, specialist availability, medication accessibility, and treatment protocol standardization.
Main Results:
- Key challenges include low awareness of MS among the public and healthcare professionals, a shortage of neurologists, and high costs of MS medications rendering them inaccessible.
- Lack of standardized treatment protocols and specialized diagnostic tools further complicates accurate diagnosis and monitoring.
- India's population diversity presents unique genetic and molecular challenges influencing treatment responses.
Conclusions:
- Improving MS diagnosis and treatment in India requires enhanced awareness and education, development of standardized care protocols, and increased investment in research and infrastructure.
- Addressing these multifaceted issues is essential for better management and improved outcomes for individuals with MS in India.

